| I‐SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy AD Barker, CC Sigman, GJ Kelloff, NM Hylton, DA Berry, LJ Esserman Clinical Pharmacology & Therapeutics 86 (1), 97-100, 2009 | 811 | 2009 |
| Diagnostic Architectural and Dynamic Features at Breast MR Imaging: Multicenter Study1 MD Schnall, J Blume, DA Bluemke, GA DeAngelis, N DeBruhl, S Harms, ... Radiology 238 (1), 42-53, 2006 | 682 | 2006 |
| Magnetic resonance imaging of the breast prior to biopsy DA Bluemke, CA Gatsonis, MH Chen, GA DeAngelis, N DeBruhl, S Harms, ... Jama 292 (22), 2735-2742, 2004 | 663 | 2004 |
| Adaptive randomization of veliparib–carboplatin treatment in breast cancer HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ... New England Journal of Medicine 375 (1), 23-34, 2016 | 590 | 2016 |
| Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively … R Nanda, MC Liu, C Yau, R Shatsky, L Pusztai, A Wallace, AJ Chien, ... JAMA oncology 6 (5), 676-684, 2020 | 559 | 2020 |
| Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging L Esserman, N Hylton, L Yassa, J Barclay, S Frankel, E Sickles Journal of clinical oncology 17 (1), 110-110, 1999 | 522 | 1999 |
| Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy—results from ACRIN 6657/I-SPY TRIAL NM Hylton, JD Blume, WK Bernreuter, ED Pisano, MA Rosen, EA Morris, ... Radiology 263 (3), 663-672, 2012 | 516 | 2012 |
| Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker N Hylton Journal of clinical oncology 24 (20), 3293-3298, 2006 | 498 | 2006 |
| Screening women at high risk for breast cancer with mammography and magnetic resonance imaging CD Lehman, JD Blume, P Weatherall, D Thickman, N Hylton, E Warner, ... Cancer 103 (9), 1898-1905, 2005 | 494 | 2005 |
| Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657 LJ Esserman, DA Berry, A DeMichele, L Carey, SE Davis, M Buxton, ... Journal of Clinical Oncology 30 (26), 3242-3249, 2012 | 493 | 2012 |
| Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy SC Partridge, JE Gibbs, Y Lu, LJ Esserman, D Sudilovsky, NM Hylton American Journal of Roentgenology 179 (5), 1193-1199, 2002 | 417 | 2002 |
| Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) LJ Esserman, DA Berry, MCU Cheang, C Yau, CM Perou, L Carey, ... Breast cancer research and treatment 132, 1049-1062, 2012 | 374 | 2012 |
| Adaptive randomization of neratinib in early breast cancer JW Park, MC Liu, D Yee, C Yau, LJ van’t Veer, WF Symmans, M Paoloni, ... New England Journal of Medicine 375 (1), 11-22, 2016 | 364 | 2016 |
| MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival SC Partridge, JE Gibbs, Y Lu, LJ Esserman, D Tripathy, DS Wolverton, ... American Journal of Roentgenology 184 (6), 1774-1781, 2005 | 336 | 2005 |
| Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability K Kinkel, TH Helbich, LJ Esserman, J Barclay, EH Schwerin, EA Sickles, ... American journal of Roentgenology 175 (1), 35-43, 2000 | 325 | 2000 |
| Development, standardization, and testing of a lexicon for reporting contrast‐enhanced breast magnetic resonance imaging studies DM Ikeda, NM Hylton, K Kinkel, MG Hochman, CK Kuhl, WA Kaiser, ... Journal of Magnetic Resonance Imaging: An Official Journal of the …, 2001 | 300 | 2001 |
| Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference TA Buchholz, CD Lehman, JR Harris, BA Pockaj, N Khouri, NF Hylton, ... Journal of Clinical Oncology 26 (5), 791-797, 2008 | 268 | 2008 |
| Neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival—results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL NM Hylton, CA Gatsonis, MA Rosen, CD Lehman, DC Newitt, ... Radiology 279 (1), 44-55, 2016 | 266 | 2016 |
| Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: the ACRIN 6698 multicenter trial SC Partridge, Z Zhang, DC Newitt, JE Gibbs, TL Chenevert, MA Rosen, ... Radiology 289 (3), 618-627, 2018 | 252 | 2018 |
| Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2. R Nanda, MC Liu, C Yau, S Asare, N Hylton, LV Veer, J Perlmutter, ... Journal of Clinical Oncology 35 (15_suppl), 506-506, 2017 | 250 | 2017 |
laura essermanProfessor of Surgery and Radiology, University of California, San Francisco在 ucsf.edu 的电子邮件经过验证
